Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
295 studies found for:    sirolimus cancer | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer
Intervention: Drug: Everolimus plus Exemestane
22 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
23 Recruiting Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Conditions: Neoplasms,;   Breast Neoplasms,;   Kidney Neoplasms,;   Pancreatic Neuroendocine Neoplasms
Interventions: Drug: alpelisib;   Drug: everolimus;   Drug: exemestane
24 Recruiting Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer
Intervention: Drug: everolimus and letrozole
25 Recruiting Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Letrozole;   Drug: Everolimus;   Drug: TRC105
26 Recruiting ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
Condition: Prostate Cancer
Interventions: Drug: ARN-509;   Drug: Everolimus
27 Recruiting Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor-negative;   Stage IV Breast Cancer;   Triple-negative Breast Carcinoma
Interventions: Drug: everolimus;   Drug: eribulin mesylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
28 Recruiting Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer
Condition: Refractory Hurthle Cell Thyroid Cancer
Interventions: Drug: sorafenib;   Drug: everolimus
29 Recruiting VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors
Conditions: Adenocarcinoma;   Pancreatic Neoplasms
Interventions: Drug: X-82;   Drug: Everolimus;   Procedure: Blood draws for pharmacokinetic testing
30 Not yet recruiting Everolimus trIal for Advanced prememopausaL Breast Cancer Patients
Condition: Metastatic Breast Cancer
Interventions: Drug: Everolimus;   Drug: Goserelin;   Drug: Letrozole
31 Recruiting DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).
Conditions: HER2-negative Und Hormone-receptor Positive Metastatic Breast Cancer;   HER2-negative Circulating Tumor Cells;   Postmenopausal Female Patients
Interventions: Drug: Everolimus;   Drug: Eribulin
32 Recruiting A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Conditions: Solid Tumors;   Lung Cancer
Interventions: Drug: BKM120;   Drug: Everolimus
33 Recruiting Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors
Condition: Cancer
Interventions: Drug: Sirolimus;   Drug: Celecoxib;   Drug: Etoposide;   Drug: Cyclophosphamide
34 Recruiting Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Condition: Breast Cancer
Interventions: Drug: Ribociclib;   Drug: Everolimus;   Drug: Exemestane
35 Recruiting A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: Dasatinib;   Drug: Cyclophosphamide;   Drug: Temsirolimus
36 Recruiting Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy
Conditions: Primary Non-metastatic Breast Cancer;   Who Remain Disease-free
Interventions: Drug: Everolimus;   Drug: Placebo
37 Recruiting A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
Condition: Desmoid Tumor
Intervention: Drug: Sirolimus
38 Recruiting Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Carcinoma;   Lung Adenocarcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Squamous Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Auranofin;   Drug: Sirolimus;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
39 Recruiting A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
Condition: Relapsed / Recurrent Germ Cell Tumors
Interventions: Drug: Erlotinib;   Drug: Sirolimus
40 Recruiting Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
Conditions: Advanced Malignant Neoplasm;   Cervical Squamous Cell Carcinoma;   Endometrial Carcinoma;   Malignant Uterine Neoplasm;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Head and Neck Carcinoma;   Recurrent Malignant Neoplasm;   Recurrent Ovarian Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Solid Neoplasm;   Stage III Bladder Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Cervical Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Breast Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Breast Cancer;   Stage IV Ovarian Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IVA Bladder Cancer;   Stage IVA Cervical Cancer;   Stage IVB Bladder Cancer;   Stage IVB Cervical Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nanoparticle Albumin-Bound Rapamycin;   Other: Quality-of-Life Assessment

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years